Arcutis Biotherapeutics
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Arcutis Biotherapeutics is Medium Risk. The company often yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Arcutis Biotherapeutics occasionally embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues at times. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportHas canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.
Arcutis Biotherapeutics integrates ESG into its business practices. From its 2023 ESG Report: “As we continue to scale our operations as an early commercial-stage company, ESG will remain ingrained in our strategy” (1). However, the company has not canceled customers, suppliers, or vendors based on political views or religious beliefs (2).
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Arcutis Biotherapeutics does not appear to discriminate against charitable organizations based on views or beliefs (1).
Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.
Arcutis Biotherapeutics appears to prioritize diversity over merit in its hiring. From its ESG webpage: “Diversity, equity, and inclusion are core belief systems woven into our practices, from how we hire to how we conduct clinical trials” (1). The company does not provide viewpoint protections for its employees (2).
Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.
Arcutis Biotherapeutics supports DEI within its business practices. From its 2023 ESG Report: “Arcutis relies on diverse representation across our operations, among our employee base, in our leadership ranks, and in clinical trials to ensure our culture and our processes are equitable and inclusive” (1). The company supports ESG within its business practices. From its 2023 ESG Report: “We have assembled an executive-level cross-functional ESG team, led by our Head of ESG, with ESG reporting into the Nominating and Governance Committee of the Board of Directors” (2)(3).
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
Arcutis Biotherapeutics has not used corporate funds to advance ideological causes, organizations, or policies (1).
Board Bias
Expand Summary
1792 Exchange has not yet compiled data about the board of directors or political contributions of leadership for this company.